Hypermetabolic lesions of the pancreas on FDG PET/CT

Clinical Nuclear Medicine

Volumn 38, Issue 9, 2013, Pages

  Dong, Aisheng ^a   Dong, Hui ^b   Zhang, Ling ^a   Zuo, Changjing ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

FDG; infection (Clin Nucl Med 2013; 38: e354Ye366); pancreas; pancreatic cancer; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; AUTOIMMUNE PANCREATITIS; CHRONIC PANCREATITIS; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; FEMALE; HUMAN; HYPERMETABOLISM; LYMPHOMA; MALE; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PANCREAS CYST; PANCREAS DISEASE; PANCREATITIS; SOLID PSEUDOPAPILLARY TUMOR;

EID: 84883454651     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182708503     Document Type: Article

References (52)

1. Bang S, Chung HW, Park SW, et al. The clinical usefulness of 18- fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and esponse evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol. 2006;40:923-929.
2. Grassetto G, Rubello D. Role of FDG-PET/CT in diagnosis, staging, response to treatment, and prognosis of pancreatic cancer. Am J Clin Oncol. 2011; 34:111-114.
3. Takanami K, AbeK,MitamuraA, et al. Two cases of 18F-FDG PET/CT findings in acinar cell carcinoma of the pancreas. Clin Nucl Med. 2009;34:209-212.
4. Schick V, Franzius C, Beyna T, et al. Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur J Nucl Med Mol Imaging. 2008;35:1775-1785.
5. Saif MW, Cornfeld D, Modarresifar H, et al. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: Initial experience in 12 patients. J Gastrointestin Liver Dis. 2008;17:173-178.
6. Kauhanen SP, Komar G, Seppanen MP, et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg. 2009;250:957-963.
7. Heinrich S, Goerres GW, Schafer M, et al. Positron emission tomography/ computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg. 2005;242:235-243.
8. Casneuf V, Delrue L, Kelles A, et al. Is combined 18F- fluorodeoxyglucosepositron emission tomography/computed tomography superior to positron emission tomography r computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Acta Gastroenterol Belg. 2007;70:331-338.
9. Sperti C, Pasquali C, Chierichetti F, et al. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Ann Surg. 2001;234:675-680.
10. Sperti C, Pasquali C, Decet G, et al. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: A prospective study. J Gastrointest Surg. 2005;9:22-28.
11. Inokuma T, Tamaki N, Torizuka T, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: Comparison with CT and US. Radiology. 1995;195:345-352.
12. Mansour JC, Schwartz L, Pandit-Taskar N, et al. The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. J Gastrointest Surg. 2006;10:1354-1360.
13. Sato M, Hiyama T, Kato K, et al. F-18 FDG accumulation in mucinous cystic neoplasm of pancreas. Clin Nucl Med. 2011;36:45-48.
14. Sperti C, Bissoli S, Pasquali C, et al. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2007; 246:932-937.
15. Hong HS, Yun M, Cho A, et al. The utility of F-18 FDG PET/CT in the evaluation of pancreatic intraductal papillary mucinous neoplasm. Clin Nucl Med. 2010;35:776-779.
16. Papavramidis T, Papavramidis S. Solid pseudopapillary tumors of the pancreas: Review of 718 patients reported in English literature. J Am Coll Surg. 2005; 200:965-972.
17. Butte JM, Brennan MF, Gonen M, et al. Solid pseudopapillary tumors of the pancreas. Clinical features, surgical outcomes, and long-term survival in 45 onsecutive patients from a single center. J Gastrointest Surg. 2011;15:350-357.
18. Shimada K, Nakamoto Y, Isoda H, et al. F-18 fluorodeoxyglucose uptake in a solid pseudopapillary tumor of the pancreas mimicking malignancy. Clin Nucl Med. 2008;33:766-768.
19. Lee JK, Tyan YS. Detection of a solid pseudopapillary tumor of the pancreas with F-18 FDG positron emission tomography. Clin Nucl Med. 2005;30:187-188.
20. Roldán-Valadez E, Rumoroso-Garc?́a A, Vega-González I, et al. Non-resected solid papillary epithelial tumor of the pancreas: 18F-FDG PET/CTevaluation at 5 years after diagnosis. Rev Esp Med Nucl. 2007;26:160-164.
21. Nakagohri T, Kinoshita T, Konishi M, et al. Surgical outcome of solid pseudopapillary tumor of the pancreas. J Hepatobiliary Pancreat Surg. 2008;15:318-321.
22. Kang CM, Kim KS, Choi JS, et al. Solid pseudopapillary tumor of the pancreas suggesting malignant potential. Pancreas. 2006;32:276-280.
23. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753-781.
24. DeLellis RA, Lloyd RV. World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon, France: IARC; 2004:175-207.
25. Adams S, Baum R, Rink T, et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998;25:79-83.
26. Pasquali C, Rubello D, Sperti C, et al. Neuroendocrine tumor imaging: Can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg. 1998;22:588-592.
27. Nakamoto Y, Higashi T, Sakahara H, et al. Evaluation of pancreatic islet cell tumors by fluorine-18 fluorodeoxyglucose positron emission tomography: Comparison with other modalities. Clin Nucl Med. 2000;25:115-119.
28. Webb TH, Lillemoe KD, Pitt HA, et al. Pancreatic lymphoma. Is surgery mandatory for diagnosis or treatment? Ann Surg. 1989;209:25Y30
29. Rosenberg SA, Diamond HD, Jaslowitz B, et al. Lymphosarcoma: A review of 1269 cases. Medicine (Baltimore). 1961;40:31-84.
30. Merkle EM, Bender GN, Brambs HJ. Imaging findings in pancreatic lymphoma: Differential aspects. AJR Am J Roentgenol. 2000;174:671-675.
31. Yoon SN, Lee MH, Yoon JK. F-18 FDG positron emission tomography findings in primary pancreatic lymphoma. Clin Nucl Med. 2004;29:574-575.
32. Tang S, Huang G, Liu J, et al. Usefulness of 18F-FDG PET, combined FDGPET/CT and EUS in diagnosing primary pancreatic carcinoma: A meta-analysis. Eur J Radiol. 2011;78:142-150.
33. Nguyen VX, Nguyen CC, Nguyen BD. 18F-FDG PET/CT imaging of the pancreas: Spectrum of diseases. JOP. 2011;12:557-566.
34. Higashi T, Saga T, Nakamoto Y, et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)Vusefulness and limitations in ''clinical reality''. Ann Nucl Med. 2003; 17:261-279.
35. Jeong Yoon S, Lee B, Park CH. Imaging diagnosis of post-ERCP focal pancreatitis mimicking pancreatic carcinoma by follow-up F-18 FDG PET/CT. Clin Nucl Med. 2011;36:70-72.
36. van Kouwen MC, Jansen JB, van Goor H, et al. FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. Eur J Nucl Med Mol Imaging. 2005;32:399-404.
37. Papós M, Takács T, Trón L, et al. The possible role of F-18 FDG positron emission tomography in the differential diagnosis of focal pancreatic lesions. Clin Nucl Med. 2002;27:197-201.
38. YokoyamaY,NaginoM,HiromatsuT, et al. Intense PET signal in the degenerative necrosis superimposed on chronic pancreatitis. Pancreas. 2005;31:192-194.
39. Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med. 1998;25:259-264.
40. Lorén I, Lasson A, Fork T, et al. New sonographic imaging observations in focal pancreatitis. Eur Radiol. 1999;9:862-867.
41. Neff CC, Simeone JF, Wittenberg J, et al. Inflammatory pancreatic masses. Problems in differentiating focal pancreatitis from carcinoma. Radiology. 1984;150:35-38.
42. Pamuklar E, Semelka RC. MR imaging of the pancreas. Magn Reson Imaging Clin N Am. 2005;13:313-330.
43. Nishi M, Ikegami T, Imura S, et al. Mass-forming pancreatitis with positive fluoro-2-deoxy-D: -glucose positron emission tomography and positive diffusion-weighted imaging-magnetic resonance imaging: Report of a case. Surg Today. 2009;39:157-161.
44. Sarles H, Sarles JC, Muratore R, et al. Chronic inflammatory sclerosis of the pancreasVan autonomous pancreatic disease? Am J Dig Dis. 1961;6:688-698.
45. Deshpande V, Mino-Kenudson M, Brugge W, et al. Autoimmune pancreatitis: more than just a pancreatic disease? A contemporary review of its pathology. Arch Pathol Lab Med. 2005;129:1148-1154.
46. Lee TY, Kim MH, Park do H, et al. Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR Am J Roentgenol. 2009;193:343-348.
47. Ozaki Y, Oguchi K, Hamano H, et al. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastroenterol. 2008;43:144-151.
48. Nakajo M, Jinnouchi S, Noguchi M, et al. FDG PET and PET/CT monitoring of autoimmune pancreatitis associated with extrapancreatic autoimmune disease. Clin Nucl Med. 2007;32:282-285.
49. Bradley EL 3rd. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, GA, September 11 through 13, 1992. Arch Surg. 1993;128:586-590.
50. Habashi S, Draganov PV. Pancreatic pseudocyst. World J Gastroenterol. 2009;15:38-47.
51. Huang B, Puri S. Pancreatic pseudocyst observed on F-18 FDG PET imaging. Clin Nucl Med. 2005;30:259-261.
52. Sanabe N, Ikematsu Y, Nishiwaki Y, et al. Pancreatic tuberculosis. J Hepatobiliary Pancreat Surg. 2002;9:515-518.